Abcam’s new premium-grade bioactive proteins, for drug discovery, development and manufacturing

Cambridge, UK, 3rd November 2020 – Abcam’s new premium-grade bioactive proteins are highly-active growth factors and cytokines manufactured and designed to meet the specific needs of cell culture, including cell and gene therapy and regenerative medicine.

Sourcing high-quality proteins with batch-to-batch consistency can be a challenge, as endotoxin levels and/or non-native protein conformations and post-translational modifications can affect safety and performance.

Abcam’s new premium-grade proteins are manufactured in mammalian cell lines under animal-free conditions limiting endotoxins to ultra-low levels (< 5 EU/mg). The use of mammalian cell lines produces proteins with the desired conformation and correct post-translational modifications for optimal bioactivity. They resemble the proteins’ native state, helping to ensure a safe and consistent outcome during drug discovery, development and manufacturing.

Developed by a team of industry-expert protein scientists, each batch is validated using state-of-the-art technology to ensure consistent quality regarding integrity, purity, concentration, mono-dispersity and correct folding.

Abcam can also design, manufacture and validate proteins to custom needs and specifications. As a supplier of proteins for a broad range of applications, Abcam provides a comprehensive range of bioactive and research-grade proteins that enable additional cost-effective quality solutions.

 

Abcam’s premium-grade bioactive proteins provide:

  • Superb bioactivity
  • Ultra-low endotoxin levels, < 5 EU/mg
  • Native post-translational modifications
  • > 95% purity
  • Carrier-free, tag-free
  • Manufactured under ISO9001
  • Batch-to-batch consistency monitored by sophisticated quality control, addressing identity, integrity, purity, concentration, folding and aggregation using methods such as LCMS, light scattering and thermal denaturation
  • Premium protein product certificate of analysis provided

 

- ENDS -

 

Notes to Editors

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.

Abcam partners with life science organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading, antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products.

With twelve sites globally, many of Abcam's 1,500 strong team are located in the world's leading life science research hubs, complementing a global network of services and support.

To find out more, please visit www.abcam.com and  www.abcamplc.com.

 

For more information please contact: 


Abcam’s External Communications team

E: external.comms@abcam.com

Back to news